Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MC-1-50 in R/R CD19+ B-NHL
NCT06180174Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PTOC1 in B-cell non-Hodgkin lymphoma, sponsored by Chongqing Precision Biotech. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 1 month. Started Dec 2023; status: recruiting.
02
Drugs
PTOC1
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06180174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06180174.